by The Oral Biologics Market offers a range of oral biologics formulations including monoclonal antibodies, vaccines, peptides and proteins that provide several advantages over injectable formulations such as improved patient adherence and convenience. Oral biologics are anticipated to revolutionize the delivery of biologics therapy by enabling targeted delivery and absorption directly into systemic circulation.
The Global Oral Biologics Market is estimated to be valued at US$ 4.81 Bn in 2024 and is expected to exhibit a CAGR of 35% over the forecast period 2024 To 2031.
Key Takeaways
Key players operating in the Oral Biologics are Novo Nordisk A/S, Biocon Limited, Oramed Pharmaceuticals, Inc., Rani Therapeutics, Entera Bio Ltd., AbbVie Inc., Enteris BioPharma, Inc., Chiasma, Inc. and Allena Pharmaceuticals, Inc. Key players are majorly focusing on developing novel oral delivery platforms to deliver large molecule biologics.
The global Oral Biologics Market Demand is increasing rapidly mainly due to the growing prevalence of chronic diseases worldwide. Additionally, the advantages of oral formulations over injections including convenient self-administration and improved patient compliance are further driving the demand for oral biologics.
Major pharmaceutical companies are also strategically expanding their oral biologics pipeline through acquisitions and partnerships to strengthen their global market position. For instance, in 2021, Novo Nordisk acquired Emisphere Technologies to enhance its oral formulations development capabilities.
Market key trends
One of the major trends anticipated to drive the oral biologics market is the growing preference for oral routes of drug administration. Due to the inherent benefits of oral forms, manufacturers as well as patients are increasingly preferring oral biologic drugs over conventional injectables. This has prompted major biopharmaceutical players to invest heavily in the research and development of advanced oral delivery platforms to enable oral delivery of biologics. It is expected that the emergence of novel oral formulations will accelerate the clinical translation and commercialization of oral biologics in the coming years.
Porter’s Analysis
Threat of new entrants: High capital requirements and risks involved in R&D act as barriers for new companies.
Bargaining power of buyers: Large buyers have significant bargaining power due to availability of alternative treatment options.
Bargaining power of suppliers: Suppliers have low bargaining power due to availability of substitutes and focus on innovations.
Threat of new substitutes: Threat of new substitutes is high due to ongoing research in novel drug delivery technologies.
Competitive rivalry: Intense competition exists among existing players to develop improved products.
Geographical Regions
North America currently holds the largest share of the global oral biologics market owing to rapid adoption of novel technologies, presence of major players, and favorable reimbursement policies. Asia Pacific is expected to grow at the highest CAGR during the forecast period due to rising healthcare spending, increasing collaboration between private and public healthcare systems, and growing awareness regarding treatment of chronic diseases.
Geographical Regions
Europe accounts for significant market share due to increasing R&D investment, availability of favorable funding schemes, and expanding geographical presence of key companies. Countries such as Brazil, Mexico, and South Africa are likely to offer lucrative opportunities for regional players to strengthen their foothold. Moreover, collaborations with local distributors will help global companies penetrate emerging markets effectively.
*Note:
1. Source: Coherent Market Insights, Public Source, Desk Research
2. We have leveraged AI tools to mine information and compile it.
About Author - Priya Pandey
Priya Pandey is a dynamic and passionate editor with over three years of expertise in content editing and proofreading. Holding a bachelor's degree in biotechnology, Priya has a knack for making the content engaging. Her diverse portfolio includes editing documents across different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. Priya's meticulous attention to detail and commitment to excellence make her an invaluable asset in the world of content creation and refinement. LinkedIn Profile
